The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data

Vaccine

Volumn 20, Issue 19-20, 2002, Pages 2533-2536

  Rivest, Paul ^a,b   Allard, Robert ^a,b,c  

^a Gouvernement du Quebec   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Efficacy; Neisseria meningitidis; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RATE; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; COHORT ANALYSIS; EPIDEMIC MENINGITIS; HEALTH SURVEY; PRESCHOOL CHILD; STANDARD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMAN; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; POPULATION SURVEILLANCE; HUMANS;

EID: 0037035865     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00162-7     Document Type: Article

References (25)

1. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanent Vaccine Study Center Group
2. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group
3. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies
4. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec
5. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center
6. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools
7. The effectiveness of the varicella vaccine in clinical practice
8. Efficacy of meningococcal vaccine and barriers to vaccination
9. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population
10. Risk factors for measles and vaccine efficacy during an epidemic in Montreal
11. Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine
12. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada
13. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992
14. Vaccination massive contre les infections invasives à méningocoques dans trois régions de la province de Québec, Janvier 1992
15. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada
16. Disease-specific case definitions and surveillance methods
17. Assessing vaccine efficacy in the field. Further observations
18. Estimability and estimation in case-referent studies
19. Evaluation of the completeness of reporting of invasive meningococcal disease
20. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants
21. Vaccination programme for group C meningococcal infection is launched
22. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
23. Deaths prompt $ 100 M shots - Virulent meningitis outbreak infected 72 Quebecers
24. Toddlers to get meningococcal vaccine this fall - New vaccine the first for young infants
25. La vaccination centre la méningite commence cette semaine au Québec